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Abstract
Background: α-amylase and α-glucosidase digest the carbohydrates and increase the postprandial glucose level in
diabetic patients. Inhibiting the activity of these two enzymes can control postprandial hyperglycemia, and reduce
the risk of developing diabetes. Bitter gourd or balsam pear is one of the important medicinal plants used for
controlling postprandial hyperglycemia in diabetes patients. However, there is limited information available on the
presence of α-amylase and α-glucosidase inhibiting compounds. In the current study, the protein extracts from the
fruits of M. charantia var. charantia (MCC) and M. charantia var. muricata (MCM) were tested for α-amylase and
α-glucosidase inhibiting activities in vitro, and glucose lowering activity after oral administration in vivo.
Results: The protein extract from both MCC and MCM inhibited the activity of α-amylase and α-glucosidase
through competitive inhibition, which was on par with Acarbose as indicated by in vitro percentage of inhibition
(66 to 69 %) and IC50 (0.26 to 0.29 mg/ml). Both the protein extracts significantly reduced peak blood glucose and
area under the curve in Streptozotocin-induced diabetic rats, which were orally challenged with starch and sucrose.
Conclusions: Protein extracts from the fruits of the two varieties of bitter gourd inhibited α-amylase and
α-glucosidase in vitro and lowered the blood glucose level in vivo on par with Acarbose when orally administrated
to Streptozotocin-induced diabetic rats. Further studies on mechanism of action and methods of safe and
biologically active delivery will help to develop an anti-diabetic oral protein drug from these plants.
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Background
In diabetes mellitus, homeostasis of carbohydrate and lipid
metabolism is altered due to defects in insulin production
or action. It is a major non-communicable metabolic
disease involving huge healthcare cost and high mortality
rate. The number of adults with diabetes was estimated to
be 387 million, and diabetes alone caused 4.9 million
deaths in the year 2014 [1]. Postprandial hyperglycemia
(PPHG) is a condition in which blood glucose level
remains high after consuming meal, and it is an important
factor to be considered in the management of diabetes
mellitus and diabetes related secondary complications
such as diabetic retinopathy, diabetic neuropathy, cardio-
vascular diseases, etc. [2]. Glycosidic linkages of α-D-(1,4)
in carbohydrates are cleaved by α-amylase to produce
oligosaccharides, which are further cleaved to monosac-
charide glucose by α-glucosidase [3]. Therefore, inhibitors
of these enzymes can delay the increase in blood glucose
level in people who consume carbohydrate-rich food, and
keep the PPHG under control [4].* Correspondence: parani.m@ktr.srmuniv.ac.in
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Acarbose, Miglitol, and Voglibose are the enzyme inhibi-
tors that are currently used for controlling PPHG. Acar-
bose inhibits both α-amylase and α-glucosidase, but
Miglitol and Voglibose inhibit only α-glucosidase. Though
effective in controlling PPHG, these inhibitors are not de-
sirable for long-term treatment due to their gastrointestinal
side effects [5, 6]. Given the fact that about 80 % of the dia-
betic people are living in low and middle income countries
[7], these drugs are expensive also. Therefore, several
groups have made their efforts to find α-amylase and α-
glucosidase inhibitors from plants, bacteria, marine algae,
and fungi [8–11]. Majority of them have studied the crude
extracts (organic or aqueous), and some have studied pure
compounds also [12, 13]. Most of the plant extracts and
pure compounds were effective against either α-amylase or
α-glucosidase, with a few exceptions being effective against
both enzymes [14, 15].
Presence of antidiabetic activity in Momordica charan-
tia (bitter gourd or balsam pear) was identified as early
as in 1963 [16]. Extracts from fruit pulp, seeds, leaves
and whole plants of M. charantia were shown to have
hypoglycemic effects [17]. Methanol extracts from the
fruits and seeds of M. charantia exhibited α-glucosidase
inhibiting activity [18–20]. Fasting and postprandial
blood glucose levels in diabetes patients were reduced
after the oral intake of the aqueous extract from M.
charantia fruit pulp [21]. Clinical trials using an insulin-
like protein from M. charantia fruit pulp showed
hypoglycemic activity in diabetes patients [22]. In vivo
hypoglycemic, insulin-mimetic, and insulin secretagogue
activities were also reported for the protein extracts
from M. charantia [23, 24]. However, there was no dir-
ect evidence to show that the protein extracts from M.
charantia have α-amylase and α-glucosidase inhibiting
activities. Therefore, the current study was undertaken
to evaluate the protein extracts from the fruits of two
varieties of M. charantia for α-amylase and α-
glucosidase inhibiting activities in vitro and glucose low-
ering activity in vivo using Acarbose as reference.
Methods
Materials
The fruits of M. charantia var. charantia (MCC) and M.
charantia var. muricata (MCM) were bought from the
local market in Chengalpet, Tamil Nadu, India. They were
taxonomically identified by a botanist and verified by DNA
barcoding. Porcine α-amylase and yeast α-glucosidase were
bought from Sigma Aldrich, and Acarbose from Bayer AG
(Germany).
Protein extraction
Proteins were extracted from the fruit pulp of the two
varieties of M. charantia as described before [24] with
minor modifications. Fresh pulp was ground with ice-
cold acid-ethanol, filtered through a muslin cloth, and
centrifuged at 8000 × g for 10 min. The pH of the super-
natant was adjusted to 3.0 using ammonia solution. Four
volumes of acetone was added, mixed gently, and incu-
bated at 4 °C for 24 h. The mixture was centrifuged at
6000 × g for 10 min. The pellet was washed with 80 %
acetone, air dried, and dissolved in 10 mM Tris–HCl,
pH 8.0.
α-amylase inhibition assay
Stock solutions of protein extracts and Acarbose were
prepared in water. Inhibition of porcine α-amylase activ-
ity was determined using dinitrosalicylic acid as de-
scribed before [25]. Protein extract or Acarbose (100 μl
of 2 to 20 mg/ml) was added to 100 μl of α-amylase (1
U/ml) and 200 μl of sodium phosphate buffer (20 mM,
pH 6.9) to get 0.5 to 5.0 mg/ml final concentration. The
samples were pre-incubated at 25 °C for 10 min, and
200 μl of 1 % starch prepared in 20 mM sodium phos-
phate buffer (pH 6.9) was added. The reaction mixtures
were incubated at 25 °C for 10 min. The reactions were
stopped by incubating the mixture in a boiling water
bath for 5 min after adding 1 ml of dinitrosalicylic acid.
The reaction mixtures were cooled to room temperature,
diluted to 1:5 ratio with water, and absorbance was mea-
sured in a spectrophotometer (Amersham Biosciences,
USA) at 540 nm. Percentage of inhibition of enzyme ac-
tivity was calculated as







Control is absorbance at 540 nm in control
sample without protein extract and A540
Treatment is absorb-
ance at 540 nm in treatment with protein extract
α-glucosidase inhibition assay
Inhibition of α-glucosidase activity was determined
using yeast α-glucosidase and p-nitrophenyl-α-D-glu-
copyranoside (pNPG) as described before [26]. Protein
extract or Acarbose (100 μl of 2 to 20 mg/ml) was
added to 50 μl of α-glucosidase (1 U/ml) prepared in
0.1 M phosphate buffer (pH 6.9), and 250 μl of 0.1 M
phosphate buffer to get 0.5 to 5.0 mg/ml final concen-
tration. The mixture was pre-incubated at 37 °C for
20 min. After pre-incubation, 10 μl of 10 mM pNPG
prepared in 0.1 M phosphate buffer (pH 6.9) was
added, and incubated at 37 °C for 30 min. The reac-
tions were stopped by adding 650 μl of 1 M sodium
carbonate, and the absorbance was measured in a
spectrophotometer (Amersham Biosciences, USA) at
405 nm. Percentage of inhibition of enzyme activity
was calculated as
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Control is absorbance at 405 nm in control
sample without protein extract and A405
Treatment is absorb-
ance at 405 nm in treatment with protein extract
Analysis of proteolytic activity
Proteolytic activity of the plant extracts was tested
against α-amylase (2 U/ml), α-glucosidase (0.05 U/ml)
and a mixture of six unrelated proteins (β-lactalbumin,
lysozyme, soybean trypsin inhibitor, ovalbumin, bovine
serum albumin, and phosphorylase-b, 5 μg). These sam-
ples were treated with 20 μg of the protein extracts from
MCC and MCM for 10 min at 25 °C (α-amylase and
mixture of six proteins) or 37 °C (α-glucosidase). Treat-
ment with Proteinase K (55 °C for 1 h), and heat dena-
tured protein extracts were used as positive and negative
controls, respectively. The reactions were stopped by
heating the samples at 100 °C for 5 min after adding
protein loading dye to a final concentration of 1X. The
samples were analyzed by 12 % SDS-PAGE.
Mode of inhibition assay
Mode of inhibition of α-amylase and α-glucosidase by
the protein extracts was determined as described before
[27]. For α-amylase, the enzyme solution (1 U/ml) was
pre-incubated with protein extracts (10 mg/ml), Acar-
bose (10 mg/ml) or phosphate buffer (pH 6.9) at 25 °C
for 10 min. The reactions were started by adding 5 to
25 mg/ml starch, and continued at 25 °C for 10 min.
The reactions were stopped by adding 0.5 ml of dinitro-
salicylic acid followed by boiling for 5 min. For α-
glucosidase, the enzyme solution (1 U/ml) was pre-
incubated with protein extracts (10 mg/ml), Acarbose
(10 mg/ml) or phosphate buffer (pH 6.9) at 25 °C for
10 min. The reactions were started by adding 50 to
250 mg/ml pNPG, and continued at 25 °C for 10 min.
The reactions were stopped by adding 0.05 ml of 1 M
sodium carbonate. Release of reducing sugars was quan-
tified using maltose and paranitrophenol standard curve.
Double reciprocal plot (1/v versus 1/[S]) where v is reac-
tion velocity and [S] is substrate concentration was plot-
ted. Mode of inhibition was determined by analysing
Lineweaver-Burk plot using Michaelis-Menten kinetics.
Induction of diabetes in Wistar rats
Forty male Wistar rats (3-months old) were purchased
from King’s Institute, Chennai, and kept under 12:12 h
light and dark cycle at 25 ± 2 °C. The diabetic animals
were fed with high fat diet and water ad libitum through-
out the treatment period of 30 days. The experimental
protocols were conducted in accordance with internation-
ally accepted principles for laboratory animal use and were
approved by the Institutional Animal Ethical Committee
(087/835/IAEC-2014). Diabetes was induced in 18 h fasted
animals by intraperitoneal injection of 110 mg/kg nico-
tinamide followed by 45 mg/kg Streptozotocin (freshly
dissolved in 0.1 M citrate buffer, pH 4.5). Tail bleeds were
performed 7 days after injecting Streptozotocin, and ani-
mals with blood glucose concentration above 250 mg/dL
were considered diabetic.
Oral starch and sucrose tolerance tests
Oral starch and sucrose tolerance tests were performed
as described before [28]. Twenty fasted diabetic and
non-diabetic rats were divided into four groups of five
each, and orally treated with 10 mg/kg body weight of
the protein from MCC, MCM, Acarbose (positive con-
trol) or distilled water (negative control). Ten minutes
after the treatment, blood glucose level was estimated
(0 min), and the rats were orally administered with
3.0 g/kg starch or 4.0 g/kg sucrose. Blood glucose level
(BG) was estimated 30, 60 and 120 min after the admin-
istration. Peak blood glucose (PBG) was determined by
observing the blood glucose level during the above men-
tioned time intervals and area under the curve (AUC)
was calculated using the formula given below
AUC mg=dL: Hð Þ ¼ BG0 þ BG30x 0:5ð Þ=2
þ BG30 þ BG60x 0:5ð Þ=2
þ BG60 þ BG120x 1:0ð Þ=2
wherein BG0 is the blood glucose level before oral ad-
ministration of starch and glucose, and BG30, BG60, and
BG120 are the blood glucose level 30, 60 and 120 min
after the administration.
Statistical analysis
All experiments were performed in triplicate. Means,
standard errors, and standard deviations were calculated
from replicates within the experiments. Statistical ana-
lysis was done by one way analysis of variance
(ANOVA). Statistical significance was accepted at P <
0.05. IC50 was calculated using graph pad prism
software.
Results
α -amylase inhibition assay
Fruit pulp of M. charantia var. charantia (MCC) and M.
charantia var. muricata (MCM) yielded 0.07 and
0.025 % proteins on wet weight basis, respectively. Inhib-
ition of α-amylase activity by the protein extracts from
MCC, MCM and Acarbose was found to be dose
dependent from 0.5 to 2.5 mg/ml concentrations (Fig. 1).
A maximum of 66.5, 67 and 68 % inhibition of α-amylase
activity was observed at 2.5 mg/ml concentration for the
protein extracts from MCC, MCM and Acarbose, respect-
ively. Heat denatured protein extracts from MCC and
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MCM showed only a maximum of 11 % α-amylase inhib-
ition activity at this concentration. The IC50 was 0.267 ±
0.024, 0.261 ± 0.019, and 0.258 ± 0.017 mg/ml for the pro-
tein extracts from MCC, MCM, and Acarbose, respectively
(Table 1). The percentage inhibition of α-amylase activity
and IC50 of the protein extracts from MCC and MCM was
highly significant (P < 0.05) when compared with the heat
denatured protein extracts but not with Acarbose.
α -glucosidase inhibition assay
Ability of the protein extracts from MCC and MCM to in-
hibit α- glucosidase enzyme activity was determined at dif-
ferent concentrations between 0.5 and 5.0 mg/ml. Protein
extracts from both MCC and MCM showed α-glucosidase
inhibition activity in a dose dependant manner from 0.5 to
2.5 mg/ml concentration (Fig. 1). A maximum of 68.8, 69.2
and 70 % inhibition of α-glucosidase activity was observed
at 2.5 mg/ml concentration for the protein extracts from
MCC, MCM and Acarbose, respectively. Heat denatured
protein extracts from MCC and MCM showed only a max-
imum of 10 % α-glucosidase inhibition activity at this con-
centration. The IC50 was 0.298 ± 0.034, 0.292 ± 0.022, and
0.28 ± 0.019 mg/ml for the protein extracts from MCC,
MCM, and Acarbose, respectively (Table 1). The percentage
inhibition of α-glucosidase activity and IC50 of protein
extracts from MCC and MCM was highly significant (P <
0.05) when compared with heat denatured protein extracts
but not with Acarbose.
Analysis of proteolytic activity
Treatment with the protein extracts from MCC and
MCM did not degrade α -amylase, α-glucosidase or the
mixture of six unrelated proteins. The same result was
observed when the protein extracts were heat denatured
before the treatment. Treatment with Proteinase K
showed complete degradation of the proteins (Fig. 2).
Mode of inhibition assay
In the presence of the protein extracts from MCC and
MCM, Km increased (3.214 to 4.235 and 4.583) but Vmax
remained constant, which indicated competitive inhibition
of the α-amylase enzyme activity (Fig. 3). The same mode
of inhibition was observed against α-glucosidase enzyme
also because Km increased from 3.734 to 4.564 (MCC)
and 4.789 (MCM) but Vmax remained constant (Fig. 3).
Oral starch and sucrose tolerance tests
In both oral starch and sucrose tolerance tests, the
groups that were treated with the protein extracts from
MCC and MCM showed significant lowering of PBG
and AUC when compared with the diabetic control
group but not with the Acarbose-treated group (Fig. 4,
Table 2, P < 0.05). In the groups that were treated with
the protein extracts from MCC and MCM, the glucose
level was reduced after 30 min in starch tolerance test,
but only after 60 min in sucrose tolerance test. In
Acarbose-treated group, the glucose level was reduced
after 60 min in both the tests.
Fig. 1 Percentage inhibition of α-amylase (a) and α-glucosidase (b) enzyme activity at different concentrations of Acarbose, protein extracts from
MCC and MCM, and heat denatured protein extracts from MCC and MCM
Table 1 IC50 values of Acarbose and protein extracts from MCC
and MCM for α-amylase and α-glucosidase inhibition
Analyte IC50 (mg/ml)
α-amylase α-glucosidase
Acarbose 0.258 ± 0.017 0.28 ± 0.019
MCC 0.267 ± 0.024 0.298 ± 0.034
MCM 0.261 ± 0.019 0.292 ± 0.022
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Discussion
Undesirable side effects and high cost of the currently
available synthetic α-glucosidase inhibitors drive the need
to explore the natural sources for new inhibitors. Being a
global lifestyle disorder that affects millions of people with
diverse genetic backgrounds, the search for alternate in-
hibitors is also desirable from the pharmacogenetics point
of view. Crude extracts and purified compounds from M.
charantia were reported to show anti-diabetic activities,
which includes α-glucosidase inhibitory activity of the
Fig. 2 SDS-PAGE analysis of α-amylase, α-glucosidase and the protein mixture after treatment with the protein extracts from MCC and MCM. The
figure shows protein marker (M), un-treated α-amylase/α-glucosidase/protein mixture (1), α-amylase/α-glucosidase/protein mixture treated with
protein extracts (2) or heat denatured protein extracts (3) or Proteinase K (4)
Fig. 3 Lineweaver-Burk plots analysis of inhibition kinetics of α-amylase and α-glucosidase enzymes by the protein extracts from MCC and MCM.
▲, ■, 10 mg/ml protein extracts; □ 20 mM phosphate buffer
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methanol and aqueous extracts [18–20]. However, α-
amylase inhibiting activity was not reported for any ex-
tract or pure compound from this plant, and its protein
extract was not studied for enzyme inhibitors against ei-
ther α-amylase or α-glucosidase. Prospective inhibitors for
controlling PPHG should have the ability to inhibit both
α-amylase and α-glucosidase with higher percentage of in-
hibition and lower IC50. Therefore, protein extracts from
M. charantia var. charantia (MCC) and M. charantia var.
muricata (MCM) were studied for their ability to inhibit
both α-amylase and α-glucosidase enzymes in vitro.
A few studies have reported that α-amylase and α-
glucosidase inhibitory activity of Acarbose may range be-
tween 55 and 82 % depending on the experimental condi-
tions [14, 15, 29]. In our study, 10 mg/ml Acarbose showed
68 and 70 % inhibition of α-amylase and α-glucosidase ac-
tivity, respectively. Under the same experimental condi-
tions, the protein extracts from both MCC and MCM
showed enzyme inhibition and IC50 on par with Acarbose.
To our knowledge, this is the first report of a protein ex-
tract from the same plant showing both α-amylase and α-
glucosidase inhibitor activities. It remains to be studied if
these two activities are contributed by a single protein or
different proteins. Near complete abolition of the enzyme
inhibitory activities was observed when the protein extracts
from MCC and MCM were heat denatured before the
treatment. This indicated that the inhibitory compounds
present in the extracts may be protein in nature, though in-
hibition due to other thermo-labile compounds cannot be
ruled out.
The protein extracts from MCC and MCM did not
show proteolytic activity against α-amylase, α-glucosidase
or the mixture of six unrelated proteins, which indicated
the absence of proteolytic activity that is specific against
these enzymes or non-specific against proteins. Therefore,
the protein extracts do not contain any compound, which
Fig. 4 Effects of protein extracts from MCC and MCM and Acarbose on glucose concentration after the administration of 3 mg/kg starch (a), and
4 mg/kg sucrose (b) in diabetic rats. Values are the mean ± SEM (n = 5), at P < 0.05 vs. control. DC: Diabetic control, Acar: Acarbose
Table 2 Effect of Acarbose and the protein extracts from MCC and MCM on peak blood glucose (PBG) and area under the curve (AUC)



















Diabetic control 367.5 ± 0.87 702.7 ± 0.97 343 ± 0.92 646 ± 0.79
Diabetic + Acarbose 277.8 ± 0.76 24.43 520.2 ± 0.59 25.97 254.3 ± 0.69 25.86 470 ± 0.88 27.24
Diabetic + MCC 289.8 ± 0.91 21.15 524.8 ± 0.65 25.32 267 ± 0.75 22.16 474.5 ± 0.95 26.55
Diabetic + MCM 282.8 ± 0.82 23 522.8 ± 0.78 25.6 261 ± 0.87 23.91 472 ± 0.58 26.94
Control 172 ± 0.56 382 ± 0.63 184 ± 0.81 394 ± 0.64
Acarbose 151 ± 0.81 12.2 305.4 ± 0.67 20.05 146 ± 0.94 20.65 295.4 ± 0.56 25.03
MCC 161.2 ± 0.65 6.28 319.1 ± 0.82 16.47 153.8 ± 0.73 16.41 308.8 ± 0.52 21.62
MCM 155 ± 0.65 9.88 309.8 ± 0.56 18.9 150.2 ± 0.67 18.37 301.6 ± 0.82 23.45
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inhibits the activity by cleaving the enzymes. The
Lineweaver-Burk plot showed that the protein extracts in-
hibit the α-amylase and α-glucosidase enzymes by com-
petitive binding.
Enzyme inhibitory activity of the protein observed in vitro
is often not maintained in vivo, especially in case of oral ad-
ministration of protein extract which is confronted by pro-
teolytic enzymes and harsh pH conditions. However, orally
administered proteins and peptides from plants have shown
significant decrease in blood glucose level indicating bio-
logically functional activity in vivo [30, 31]. We have tested
the protein extracts from MCC and MCM in vivo in
Streptozotocin-induced diabetic rats. Peak blood glucose
(PBG) and area under the curve (AUC) were significantly
reduced in the diabetic rats that were orally administered
with the protein extracts after starch or sucrose loading.
The protein extracts were able to lower the blood glucose
level faster than Acarbose in starch-fed diabetic rats. These
results demonstrated the glucose lowering effect of the pro-
tein extracts in vivo, possibly due to the α-amylase and α-
glucosidase inhibiting activities observed in vitro. However,
further experiments will be needed to confirm the same or
to find other possible mechanisms. Earlier studies in M.
charantia have shown insulin-mimetic and insulin secreta-
gogue activities in the protein extract [24], and anti-oxidant
activity in the aqueous extract [32]. Therefore, the protein
extract from M. charantia may work against diabetes
through multiple mechanisms to be useful for the holistic
management of diabetes mellitus.
Conclusion
M. charantia is a traditional medicinal plant that is
popularly used for the management of diabetes in com-
plementary and alternative medicine, and several scien-
tific lines of evidences were reported in favour of the
same. The present study established that the protein ex-
tracts from two varieties of M. charantia do have α-
amylase and α-glucosidase inhibiting activities in vitro
and glucose lowering activity in vivo. Further research is
needed to develop anti-diabetic oral protein drug from
this natural source.
Abbreviations
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